查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1806594

病毒载体和质体DNA 製造市场按产品类型、服务类型、工作流程阶段、生产平台、生物製程模式、来源、应用、最终用户和疾病领域划分 - 全球预测 2025-2030

Viral Vector & Plasmid DNA Manufacturing Market by Product Type, Service Type, Workflow Stage, Production Platform, Bioprocess Mode, Source, Application, End User, Disease Area - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年病毒载体和质体DNA 製造市场价值为 45.1 亿美元，预计到 2025 年将成长至 52.4 亿美元，复合年增长率为 16.40%，到 2030 年将达到 112.4 亿美元。

主要市场统计数据
基准年2024年 45.1亿美元
预计2025年 52.4亿美元
预测年份 2030 112.4亿美元
复合年增长率（%） 16.40%

策略介绍，解释製造稳健性、法规遵循和平台选择如何决定先进生技药品的临床和商业性成功

病毒载体和质体DNA的开发和生产支持一系列快速发展的治疗方法，从基因疗法和细胞疗法到溶瘤病毒疗法以及先进疫苗。该行业正在从概念验证迈向规模化生产，重点关注可重复性、法规遵从性和供应链弹性。因此，投资者、开发商和製造商必须将製程开发、分析严谨性和可製造性视为专案成功的策略驱动力，而非下游障碍。

深入检验模式转移的技术、监管和营运趋势，这些趋势正在重新定义尖端基因疗法的製造格局

过去几年发生了一场变革，重塑了病毒载体和质体DNA的构思、开发和生产方式。技术平台已从分散的实验室规模流程发展到更模组化、可扩展的系统，从而能够快速从实验室应用到临床应用。一次性技术、先进的生物反应器设计以及转染效率和病毒产量的提升，推动了製程集约化和批次一致性的提高。同时，分析能力也在不断发展，使得更深入的分子和功能表征成为可能，从而实现了更严格的放行标准，并提高了批次间的可比性。

对 2025 年新关税政策如何重塑生技药品製造计画的采购、资本规划和供应链弹性的策略分析。

2025年实施的政策措施为全球生技药品製造供应链带来了新的变量，影响到生产病毒载体和质体DNA所必需的试剂、耗材和专用设备。这些关税的累积影响已波及筹资策略、资本规划和合作伙伴选择，迫使企业重新评估其采购模式和合约结构。对许多公司而言，直接影响是重新调整供应商风险状况，并考虑近岸外包和多角化经营，以保障专案进度和利润。

透过与产品类型、服务、工作流程阶段、平台、流程模式、采购、应用、使用者和疾病目标相关的全面细分洞察，获得策略清晰度

要了解市场动态，需要详细了解产品类型、服务产品、工作流程阶段、平台、製程模式、采购策略、应用、最终用户和治疗领域。从产品类型的角度来看，质体DNA和病毒载体之间的差异至关重要。病毒载体本身包括腺结合病毒载体、腺病毒载体、单纯疱疹病毒载体、慢病毒载体和逆转录病毒载体，每种载体都有其独特的工艺和监管考量，这些考量会影响生产决策。分析测试、生产、製程开发、监管和CMC支援都发挥互补的作用，製程开发涵盖下游优化、製剂开发、规模化生产和技术转移以及上游优化，将早期发现与可靠的商业化生产连接起来。

区域战略观点，详细说明美洲、欧洲、中东和非洲地区以及亚太地区的不同管理体制、人才库和产能动态如何影响製造业战略

区域动态对病毒载体和质体DNA生态系统的能力发展、监管参与和商业策略产生了重大影响。在美洲，强劲的创投活动和集中的临床项目推动了对CDMO能力和高级分析的强劲需求，同时监管机构继续强调早期对话和明确的CMC预期。该地区受益于生物工艺工程和转化科学领域的深厚人才储备，但也面临技术纯熟劳工的竞争，以及对基础设施进行现代化改造以支持工艺集约化的需求。

可操作的企业策略洞察，揭示如何部署专业化、伙伴关係和营运灵活性以确保製造优势

病毒载体和质体DNA领域的领先公司正在采取各种策略手段来确保竞争优势，包括平台专业化、产能扩张和选择性垂直整合。一些公司专注于在特定载体类别或製程步骤中累积深厚的专业知识，开发专有製程技术和分析套件，以加快临床开发速度。另一些公司则优先考虑灵活性，投资模组化设施和多产品线，以支援多样化的专案并缩短转换时间。

一套优先的技术投资实用建议，以确保製造的连续性、供应链的弹性、监管参与和劳动力发展。

产业领导者应采取一系列切实有效、卓有成效的措施，以应对技术复杂性、政策不确定性和竞争压力。首先，透过优先投资能够实现模组化和高混合生产的平台，在专案管线发生变化时保持敏捷性。其次，在关键试剂和设备的供应商关係多元化的同时，开发检验的二级供应商，以降低单点故障风险。第三，在整个开发和製造过程中嵌入先进的分析和数位化品质系统，以加速对製程的理解并支持法规申报。

一种透明且可辩护的混合方法研究途径，结合专家访谈、文献综合、检验和情境分析，提供可靠的决策支持

支撑本分析的调查方法整合了主要研究方法和次要研究方法，以确保研究的稳健性、三角测量性和实用性。主要研究包括对製程开发、生产营运、品质保证和法规事务领域的专家进行结构化访谈。这些调查从申办者、服务供应商和研究机构的观点，对瓶颈、能力差距和策略重点提供了定性见解。次要研究整合了同行评审文献、监管指南、技术白皮书和公开讯息，为技术趋势和政策发展提供了背景资讯。

策略必要事项强调整合科学创新、製造严谨性和监管完整性，以确保可靠的专案进展

这项分析强调，卓越的生产製造已成为开发病毒载体和质体DNA疗法的机构的策略必要事项。製程选择、平台策略和法规准备度是相互交织的因素，决定专案能否有效率地从临床开发过渡到商业化供应。技术成熟度，加上对营运创新、分析和人才培养的有针对性的投资，使公司能够减少差异性并加快临床开发速度。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 一次性生物反应器技术在可扩展病毒载体生产的进展
  • 在质体DNA 製造过程中实施设计品质框架
  • 采用连续生产平台来简化病毒载体生产时间表
  • 整合人工智慧驱动的过程分析技术，实现即时病毒载体监测
  • 开发高保真质体骨架结构以增强基因治疗的功效
  • 透过策略CMO和生物技术伙伴关係关係扩大客製化慢病毒载体生产能力
  • 一次性切向流过滤系统对质体DNA纯化的最佳化
  • 监管协调努力塑造临床级病毒载体的全球供应链
  • 基因治疗赞助商加强垂直整合，以确保病毒载体和质体的产能，并加快CMC时间表
  • 新型衣壳和生产线的智慧财产权和专利权结构不断发展变化，将影响自主研发还是外购的决策

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

8. 病毒载体和质体DNA 製造市场（依产品类型）

  • 质体DNA
  • 病毒载体
    • 腺结合病毒载体
    • 腺病毒载体
    • 单纯疱疹病毒（HSV）载体
    • 慢病毒载体
    • 逆转录病毒载体

9. 病毒载体和质体DNA 製造市场（依服务类型）

  • 分析测试
  • 製造业
  • 製程开发
    • 下游优化
    • 配方开发
    • 扩大规模/技术转移
    • 上游最佳化
  • 监管和CMC支持

10. 病毒载体和质体DNA 製造市场（依工作流程阶段）

  • 下游加工
    • 捕获
    • 澄清
    • 浓度/缓衝液交换
    • 中间精炼
    • 抛光
  • 灌装和精加工
  • 发布和稳定性测试
  • 上游处理
    • 生物反应器生产
    • 细胞增殖
    • 转染/转导

11. 病毒载体和质体DNA 製造市场（依生产平台）

  • 细菌
  • 无细胞系统
  • 昆虫
  • 哺乳动物
  • 酵母菌

12. 病毒载体与质体DNA製造市场：生物过程模式

  • 批次
  • 文化格式
    • 贴上
    • 暂停
  • 流体化床
  • 灌注

13. 病毒载体和质体DNA 製造市场（依来源）

  • 内部製造
  • 外包/CDMO

14. 病毒载体和质体DNA製造市场（依应用）

  • 细胞疗法
  • 基因编辑
  • 基因治疗
  • 溶瘤病毒疗法
  • 研究与开发
  • 疫苗研发

15. 病毒载体和质体DNA 製造市场（依最终用户）

  • 生物製药公司
  • 合约开发和製造组织（CDMO）
  • 受託研究机构（CRO）
  • 研究所

16. 病毒载体和质体DNA製造市场（依疾病领域）

  • 心血管系统
  • 肝病
  • 感染疾病
  • 代谢/内分泌
  • 肌肉骨骼
  • 神经病学
  • 肿瘤学
  • 眼科
  • 罕见遗传疾病

17.美国病毒载体及质体DNA製造市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

18. 欧洲、中东和非洲病毒载体和质体DNA 製造市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

19. 亚太地区病毒载体及质体DNA製造市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第二十章 竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Lonza Group Ltd.
    • Merck KGaA
    • Advanced BioScience Laboratories, Inc.
    • Akron Biotech
    • Avid Bioservices, Inc.
    • Batavia Biosciences BV
    • BioNTech IMFS GmbH
    • Biovian Oy
    • c-LEcta GmbH
    • Charles River Laboratories International, Inc.
    • FILTROX AG
    • Creative Biogene
    • Forge Biologics By Ajinomoto Co., Inc.
    • FUJIFILM Diosynth Biotechnologies Inc.
    • GE HealthCare Technologies, Inc.
    • GeneOne Life Science, Inc.
    • Genezen Laboratories, Inc.
    • Kaneka Eurogentec SA
    • Miltenyi Biotec BV & Co. KG
    • Revvity, Inc.
    • REGENXBIO Inc.
    • Genentech, Inc.
    • Takara Bio Inc.
    • Thermo Fisher Scientific Inc.
    • uniQure NV
    • Wuxi AppTec Co., Ltd.
    • Catalent, Inc.
    • Oxford Biomedica plc
    • Aldevron, LLC
    • GenScript Biotech Corporation
    • POLYPLUS TRANSFECTION SA
    • Hillgene Biopharma Co., Ltd.
    • BioSpace, Inc.
    • Twist Bioscience Corporation
    • Cytiva by Danaher Corporation

第21章 研究人工智慧

第22章 研究统计

第23章 研究联络人

第24章 研究报导

第25章 附录

Product Code: MRR-030298DFFC33

The Viral Vector & Plasmid DNA Manufacturing Market was valued at USD 4.51 billion in 2024 and is projected to grow to USD 5.24 billion in 2025, with a CAGR of 16.40%, reaching USD 11.24 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 4.51 billion
Estimated Year [2025] USD 5.24 billion
Forecast Year [2030] USD 11.24 billion
CAGR (%) 16.40%

A strategic introduction describing how manufacturing robustness, regulatory alignment, and platform selection determine clinical and commercial success in advanced biologics

The development and manufacture of viral vectors and plasmid DNA now underpin a rapidly expanding set of therapeutic modalities, from gene therapies and cell therapies to oncolytic virotherapies and advanced vaccines. The industry is moving beyond proof-of-concept activity and toward production-scale realities, with an emphasis on reproducibility, regulatory compliance, and supply chain resilience. Investors, developers, and manufacturers must therefore view process development, analytical rigor, and manufacturability as strategic determinants of program success rather than downstream obstacles.

Recent technological progress has reduced some historical barriers to entry, yet it has also introduced new complexities. Advances in vector design and plasmid construct engineering have amplified demands on upstream and downstream processing, while heightened regulatory expectations have elevated the importance of quality systems and CMC documentation. Consequently, leaders must navigate a landscape where scientific innovation, manufacturing capability, and regulatory strategy converge to determine clinical and commercial viability.

Transitioning from laboratory-scale production to consistent clinical and commercial supply requires deliberate planning across platform selection, workforce competencies, and vendor ecosystems. As programs advance to later-stage clinical development, manufacturers must align process robustness with regulatory engagement, while anticipating capacity constraints and capital needs. This introduction sets the stage for a deeper examination of structural shifts, policy impacts, segmentation nuance, and actionable recommendations for organizations operating within this dynamic field.

An in-depth examination of paradigm-shifting technological, regulatory, and operational trends that are redefining the manufacturing landscape for advanced gene modalities

The last several years have seen transformative shifts that are reshaping how viral vectors and plasmid DNA are conceived, developed, and produced. Technology platforms have matured from fragmented, lab-scale processes into more modular, scalable systems, enabling faster translation from bench to clinic. Single-use technologies, advanced bioreactor designs, and improvements in transfection efficiency or viral production have driven process intensification and greater batch consistency. At the same time, analytical capabilities have evolved to provide deeper molecular and functional characterization, thereby enabling tighter release criteria and improved lot-to-lot comparability.

Concurrently, regulatory frameworks and industry expectations have moved toward greater harmonization and early engagement. Regulators increasingly emphasize control strategies, comparability demonstrations, and the use of orthogonal analytical methods to support product quality. In parallel, the growth of outsourced manufacturing and CDMO specialization is shifting strategic investment decisions: sponsors must balance in-house capabilities with the agility and scale offered by external partners. This dynamic environment is also seeing digitalization of manufacturing operations and adoption of data-driven quality systems, which together improve process control and facilitate regulatory submissions.

As a result, organizations that invest in adaptable platforms, robust analytics, and collaborative regulatory strategies are better positioned to capture the opportunities created by novel therapeutic modalities. The convergence of technological, regulatory, and commercial forces is creating an era in which manufacturing strategy is integral to therapeutic differentiation rather than a mere operational consideration.

A strategic analysis of how new tariff policies in 2025 are reshaping procurement, capital planning, and supply chain resilience for biologics manufacturing programs

Policy measures implemented in 2025 introduced a new variable into global supply chains for biologics manufacturing, with tariffs affecting reagents, consumables, and specialized equipment that are critical to viral vector and plasmid DNA production. The cumulative impact of these tariffs has rippled through procurement strategies, capital planning, and partner selection, prompting organizations to reassess sourcing models and contract structures. For many, the immediate effect has been a recalibration of supplier risk profiles and an examination of nearshoring versus diversification to protect program timelines and margins.

Beyond procurement, tariffs have influenced investment decisions around facility build-outs and equipment acquisition. Longer lead times and increased costs for certain imported components have caused some sponsors and CDMOs to reprioritize modular, flexible assets that accommodate multiple product types. In addition, contractual dynamics have shifted as buyers negotiate longer-term agreements or volume commitments to secure supply and mitigate price volatility. Fiscal unpredictability has underscored the importance of scenario planning and stress-testing supply chains against policy shocks.

To adapt, forward-looking organizations are developing mitigation strategies that include multi-sourcing critical reagents, increasing local inventory buffers for high-risk components, and collaborating more closely with suppliers to co-develop contingency plans. Engaging proactively with regulators and trade authorities also helps clarify compliance pathways for alternative materials. Ultimately, success in this environment requires a disciplined approach to procurement strategy, capital allocation, and cross-functional coordination to maintain program momentum in the face of evolving trade policy.

Comprehensive segmentation-driven insights connecting product types, services, workflow stages, platforms, process modes, sourcing, applications, users, and disease targets for strategic clarity

Understanding market dynamics requires a granular view across product types, service offerings, workflow stages, platforms, process modes, sourcing strategies, applications, end users, and therapeutic areas. From a product type perspective, distinctions between plasmid DNA and viral vectors are foundational; viral vectors themselves encompass adeno-associated viral vectors, adenoviral vectors, herpes simplex virus vectors, lentiviral vectors, and retroviral vectors, each with distinct process and regulatory considerations that shape manufacturing decision-making. Service portfolios reflect the industry's lifecycle needs: analytical testing, manufacturing, process development, and regulatory and CMC support all play complementary roles, with process development spanning downstream optimization, formulation development, scale-up and technology transfer, and upstream optimization to bridge early discovery and reliable commercial production.

The workflow stage segmentation-encompassing downstream processing, fill and finish, release and stability testing, and upstream processing-reveals opportunities and constraints that vary across process steps. Downstream activities such as capture, clarification, concentration and buffer exchange, intermediate purification, and polishing are technically demanding and often bottleneck-prone, while upstream activities like bioreactor production, cell expansion, and transfection or transduction determine yield and product quality early in the chain. Production platform choice-whether bacterial, cell-free systems, insect, mammalian, or yeast-further informs equipment selection, contamination control, and regulatory strategy.

Bioprocess mode choices including batch, culture format, fed-batch, and perfusion, with culture formats split into adherent and suspension systems, influence scale-up complexity and cost structure. Meanwhile, decisions around source-whether in-house manufacturing or outsourced CDMO partnerships-shape capital intensity and operational flexibility. Application areas from cell therapy, gene editing, gene therapy, oncolytic virotherapy, research and development, to vaccine development impose divergent quality, throughput, and timeline expectations. End users such as biopharmaceutical companies, CDMOs, CROs, and research institutions each require tailored service models, and disease area focus-spanning cardiovascular, hepatic, infectious, metabolic or endocrine, musculoskeletal, neurology, oncology, ophthalmology, and rare genetic disorders-affects regulatory pathways and commercial strategies. Synthesizing these segments reveals that technical choices and commercial models must be aligned with therapeutic goals to optimize development timelines and long-term sustainability.

Regional strategic perspectives detailing how distinct regulatory regimes, talent pools, and capacity dynamics across the Americas, EMEA, and Asia-Pacific influence manufacturing strategy

Regional dynamics exert a major influence on capability development, regulatory engagement, and commercial strategy across the viral vector and plasmid DNA ecosystem. In the Americas, robust venture activity and a dense concentration of clinical programs drive strong demand for CDMO capacity and advanced analytics, while regulatory agencies continue to emphasize early dialogue and clear CMC expectations. The region benefits from deep talent pools in bioprocess engineering and translational science, yet it also faces competition for skilled labor and the need to modernize infrastructure to support process intensification.

Europe, Middle East & Africa presents a heterogeneous landscape where established manufacturing hubs coexist with emerging centers of excellence. Regulatory regimes across the region vary, creating both opportunities for local innovation and challenges for cross-border program harmonization. Many organizations are developing regional strategies that leverage Europe's strong regulatory science base and specialized manufacturing expertise, while simultaneously managing logistics and compliance complexities that arise from multi-jurisdictional operations.

Asia-Pacific is characterized by rapidly expanding capacity, significant government support for biomanufacturing, and a growing number of specialized service providers. The region's manufacturing ecosystems are evolving quickly, with investments in both large-scale facilities and niche capabilities. As a result, Asia-Pacific is increasingly integrated into global supply chains, offering attractive options for cost-effective manufacturing, though companies must navigate differing regulatory expectations and quality assurance practices. Across all regions, successful players adapt their strategies to local strengths while maintaining global standards of quality and regulatory compliance.

Actionable corporate strategy insights revealing how specialization, partnerships, and operational flexibility are being deployed to secure manufacturing advantage

Leading organizations in the viral vector and plasmid DNA space are pursuing a range of strategic moves to secure competitive advantage, including platform specialization, targeted capacity expansion, and selective vertical integration. Some players focus on building deep expertise around particular vector classes or process steps, developing proprietary process know-how and analytical toolkits that reduce time to clinic. Others prioritize flexibility, investing in modular facilities and multi-product lines that support diverse programs and reduce changeover timelines.

Strategic partnerships and alliances are common, as sponsors collaborate with service providers to access capacity, regulatory expertise, and specialized technologies without committing to full-scale capital investments. Mergers and acquisitions have also emerged as a mechanism to accelerate capability acquisition and geographic expansion, particularly when time-to-market is critical. In parallel, investment in digital process control, quality systems modernization, and advanced analytics is helping organizations reduce variability and improve decision-making.

Collectively, these trends suggest that successful companies balance deep technical differentiation with operational elasticity. They combine scientific leadership in vector design or plasmid engineering with disciplined manufacturing and quality practices to support consistent supply. Firms that cultivate strong supplier relationships, invest in workforce development, and align commercial strategy with manufacturing capability are better positioned to support complex clinical programs and scale reliably into commercial markets.

A pragmatic set of prioritised recommendations for technology investment, supply chain resilience, regulatory engagement, and workforce development to secure manufacturing continuity

Industry leaders should adopt a set of practical, high-impact measures to navigate technological complexity, policy uncertainty, and competitive pressures. First, prioritize platform investments that enable modularity and multiproduct runs, thereby preserving agility when program pipelines shift. Second, diversify supplier relationships for critical reagents and equipment while developing verified secondary sources to reduce single-point-of-failure risks. Third, embed advanced analytics and digital quality systems across development and manufacturing to accelerate process understanding and support regulatory submissions.

Additionally, organizations should strengthen regulatory engagement by initiating early scientific advice and by validating orthogonal analytical methods that provide robust evidence of product quality. Strategic use of outsourcing for non-core functions can accelerate timelines, but it must be governed by rigorous vendor qualification and joint governance frameworks to ensure alignment on timelines and quality standards. Workforce development is equally essential; invest in targeted training that spans process development, quality, and data analytics to close skill gaps.

Finally, incorporate scenario planning into strategic reviews to stress-test programs against policy changes, supply disruptions, and shifts in demand. By combining operational resilience with focused technological investment and proactive regulatory dialogue, leaders can reduce program risk and create a foundation for sustainable growth in a rapidly evolving sector.

A transparent and defensible mixed-methods research approach combining expert interviews, literature synthesis, validation, and scenario analysis for reliable decision support

The research methodology underpinning this analysis integrates both primary and secondary approaches to ensure robustness, triangulation, and practical relevance. Primary research included structured interviews with subject-matter experts across process development, manufacturing operations, quality assurance, and regulatory affairs. These engagements provided qualitative insights into bottlenecks, capability gaps, and strategic priorities from the perspectives of sponsors, service providers, and research institutions. Secondary research synthesized peer-reviewed literature, regulatory guidance, technical white papers, and publicly available disclosures to contextualize technological trends and policy developments.

Data validation relied on cross-referencing interview findings with published process methods and regulatory precedents to confirm consistency and identify areas of divergence. Scenario analysis was used to examine the implications of policy shifts-such as tariff changes-and to model how different sourcing and capital strategies could affect program risk. The research also incorporated a review of advanced analytics and process control technologies to assess readiness for scale-up and regulatory submission.

Limitations include variability in proprietary process details and the evolving regulatory environment, which may alter guidance over time. To mitigate this, the methodology emphasizes transparency in assumptions and recommends periodic updates to reflect technological advancements and policy changes. The combined approach provides a defensible foundation for decision-making while remaining adaptable to new information.

A concise synthesis of strategic imperatives emphasizing the integration of scientific innovation, manufacturing rigor, and regulatory alignment to enable reliable program advancement

This analysis highlights that manufacturing excellence is now a strategic imperative for organizations developing viral vector and plasmid DNA therapeutics. Process selection, platform strategy, and regulatory preparedness are intertwined factors that determine whether programs can move efficiently through clinical development and into commercial supply. Technological maturation, coupled with operational innovation and targeted investments in analytics and workforce development, enables organizations to reduce variability and accelerate time to clinic.

Equally important is the need for adaptive supply chain strategies and proactive regulatory dialogue to manage external shocks such as policy changes or component shortages. Organizations that combine flexible manufacturing approaches with robust quality systems and strategic partnerships are better positioned to sustain program momentum and respond to evolving market demands. In conclusion, success in this domain will favor those who integrate scientific excellence with manufacturing pragmatism, embrace collaborative sourcing and regulatory strategies, and commit to continuous improvement of both processes and people.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Advances in single-use bioreactor technology for scalable viral vector production
  • 5.2. Implementation of quality by design frameworks in plasmid DNA manufacturing processes
  • 5.3. Adoption of continuous manufacturing platforms to streamline viral vector production timelines
  • 5.4. Integration of AI-driven process analytical technology for real-time viral vector monitoring
  • 5.5. Development of high-fidelity plasmid backbone constructs to enhance gene therapy potency
  • 5.6. Expansion of customized lentiviral vector capacity through strategic CMO and biotech partnerships
  • 5.7. Optimization of plasmid DNA purification with single-use tangential flow filtration systems
  • 5.8. Regulatory harmonization efforts shaping global supply chains for clinical-grade viral vectors
  • 5.9. Increased vertical integration by gene therapy sponsors to secure viral vector and plasmid capacity and compress CMC timelines
  • 5.10. Evolving intellectual property and royalty structures for novel capsids and producer lines influencing make-versus-buy decisions

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Viral Vector & Plasmid DNA Manufacturing Market, by Product Type

  • 8.1. Introduction
  • 8.2. Plasmid DNA
  • 8.3. Viral Vector
    • 8.3.1. Adeno-Associated Viral Vectors
    • 8.3.2. Adenoviral Vectors
    • 8.3.3. Herpes Simplex Virus (HSV) Vectors
    • 8.3.4. Lentiviral Vectors
    • 8.3.5. Retroviral Vectors

9. Viral Vector & Plasmid DNA Manufacturing Market, by Service Type

  • 9.1. Introduction
  • 9.2. Analytical Testing
  • 9.3. Manufacturing
  • 9.4. Process Development
    • 9.4.1. Downstream Optimization
    • 9.4.2. Formulation Development
    • 9.4.3. Scale-Up/Technology Transfer
    • 9.4.4. Upstream Optimization
  • 9.5. Regulatory & CMC Support

10. Viral Vector & Plasmid DNA Manufacturing Market, by Workflow Stage

  • 10.1. Introduction
  • 10.2. Downstream Processing
    • 10.2.1. Capture
    • 10.2.2. Clarification
    • 10.2.3. Concentration/Buffer Exchange
    • 10.2.4. Intermediate Purification
    • 10.2.5. Polishing
  • 10.3. Fill & Finish
  • 10.4. Release & Stability Testing
  • 10.5. Upstream Processing
    • 10.5.1. Bioreactor Production
    • 10.5.2. Cell Expansion
    • 10.5.3. Transfection/Transduction

11. Viral Vector & Plasmid DNA Manufacturing Market, by Production Platform

  • 11.1. Introduction
  • 11.2. Bacterial
  • 11.3. Cell-Free Systems
  • 11.4. Insect
  • 11.5. Mammalian
  • 11.6. Yeast

12. Viral Vector & Plasmid DNA Manufacturing Market, by Bioprocess Mode

  • 12.1. Introduction
  • 12.2. Batch
  • 12.3. Culture Format
    • 12.3.1. Adherent
    • 12.3.2. Suspension
  • 12.4. Fed-Batch
  • 12.5. Perfusion

13. Viral Vector & Plasmid DNA Manufacturing Market, by Source

  • 13.1. Introduction
  • 13.2. In-House Manufacturing
  • 13.3. Outsourced/CDMO

14. Viral Vector & Plasmid DNA Manufacturing Market, by Application

  • 14.1. Introduction
  • 14.2. Cell Therapy
  • 14.3. Gene Editing
  • 14.4. Gene Therapy
  • 14.5. Oncolytic Virotherapy
  • 14.6. Research & Developement
  • 14.7. Vaccine Development

15. Viral Vector & Plasmid DNA Manufacturing Market, by End User

  • 15.1. Introduction
  • 15.2. Biopharmaceutical Companies
  • 15.3. Contract Development & Manufacturing Organizations (CDMOs)
  • 15.4. Contract Research Organizations (CROs)
  • 15.5. Research Institutions

16. Viral Vector & Plasmid DNA Manufacturing Market, by Disease Area

  • 16.1. Introduction
  • 16.2. Cardiovascular
  • 16.3. Hepatic Diseases
  • 16.4. Infectious Diseases
  • 16.5. Metabolic/Endocrine
  • 16.6. Musculoskeletal
  • 16.7. Neurology
  • 16.8. Oncology
  • 16.9. Ophthalmology
  • 16.10. Rare Genetic Disorders

17. Americas Viral Vector & Plasmid DNA Manufacturing Market

  • 17.1. Introduction
  • 17.2. United States
  • 17.3. Canada
  • 17.4. Mexico
  • 17.5. Brazil
  • 17.6. Argentina

18. Europe, Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market

  • 18.1. Introduction
  • 18.2. United Kingdom
  • 18.3. Germany
  • 18.4. France
  • 18.5. Russia
  • 18.6. Italy
  • 18.7. Spain
  • 18.8. United Arab Emirates
  • 18.9. Saudi Arabia
  • 18.10. South Africa
  • 18.11. Denmark
  • 18.12. Netherlands
  • 18.13. Qatar
  • 18.14. Finland
  • 18.15. Sweden
  • 18.16. Nigeria
  • 18.17. Egypt
  • 18.18. Turkey
  • 18.19. Israel
  • 18.20. Norway
  • 18.21. Poland
  • 18.22. Switzerland

19. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market

  • 19.1. Introduction
  • 19.2. China
  • 19.3. India
  • 19.4. Japan
  • 19.5. Australia
  • 19.6. South Korea
  • 19.7. Indonesia
  • 19.8. Thailand
  • 19.9. Philippines
  • 19.10. Malaysia
  • 19.11. Singapore
  • 19.12. Vietnam
  • 19.13. Taiwan

20. Competitive Landscape

  • 20.1. Market Share Analysis, 2024
  • 20.2. FPNV Positioning Matrix, 2024
  • 20.3. Competitive Analysis
    • 20.3.1. Lonza Group Ltd.
    • 20.3.2. Merck KGaA
    • 20.3.3. Advanced BioScience Laboratories, Inc.
    • 20.3.4. Akron Biotech
    • 20.3.5. Avid Bioservices, Inc.
    • 20.3.6. Batavia Biosciences B.V.
    • 20.3.7. BioNTech IMFS GmbH
    • 20.3.8. Biovian Oy
    • 20.3.9. c-LEcta GmbH
    • 20.3.10. Charles River Laboratories International, Inc.
    • 20.3.11. FILTROX AG
    • 20.3.12. Creative Biogene
    • 20.3.13. Forge Biologics By Ajinomoto Co., Inc.
    • 20.3.14. FUJIFILM Diosynth Biotechnologies Inc.
    • 20.3.15. GE HealthCare Technologies, Inc.
    • 20.3.16. GeneOne Life Science, Inc.
    • 20.3.17. Genezen Laboratories, Inc.
    • 20.3.18. Kaneka Eurogentec S.A.
    • 20.3.19. Miltenyi Biotec B.V. & Co. KG
    • 20.3.20. Revvity, Inc.
    • 20.3.21. REGENXBIO Inc.
    • 20.3.22. Genentech, Inc.
    • 20.3.23. Takara Bio Inc.
    • 20.3.24. Thermo Fisher Scientific Inc.
    • 20.3.25. uniQure N.V.
    • 20.3.26. Wuxi AppTec Co., Ltd.
    • 20.3.27. Catalent, Inc.
    • 20.3.28. Oxford Biomedica plc
    • 20.3.29. Aldevron, LLC
    • 20.3.30. GenScript Biotech Corporation
    • 20.3.31. POLYPLUS TRANSFECTION S.A.
    • 20.3.32. Hillgene Biopharma Co., Ltd.
    • 20.3.33. BioSpace, Inc.
    • 20.3.34. Twist Bioscience Corporation
    • 20.3.35. Cytiva by Danaher Corporation

21. ResearchAI

22. ResearchStatistics

23. ResearchContacts

24. ResearchArticles

25. Appendix

LIST OF FIGURES

  • FIGURE 1. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 20. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2024 VS 2030 (%)
  • FIGURE 22. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 26. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 29. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 30. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 31. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 33. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: RESEARCHAI
  • FIGURE 34. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: RESEARCHSTATISTICS
  • FIGURE 35. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: RESEARCHCONTACTS
  • FIGURE 36. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRAL VECTORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RETROVIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RETROVIRAL VECTORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY MANUFACTURING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM OPTIMIZATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SCALE-UP/TECHNOLOGY TRANSFER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SCALE-UP/TECHNOLOGY TRANSFER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM OPTIMIZATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGULATORY & CMC SUPPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGULATORY & CMC SUPPORT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CAPTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CAPTURE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CLARIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CLARIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CONCENTRATION/BUFFER EXCHANGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CONCENTRATION/BUFFER EXCHANGE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INTERMEDIATE PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INTERMEDIATE PURIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY POLISHING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY POLISHING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FILL & FINISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FILL & FINISH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RELEASE & STABILITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RELEASE & STABILITY TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOREACTOR PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOREACTOR PRODUCTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL EXPANSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL EXPANSION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION/TRANSDUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION/TRANSDUCTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INSECT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INSECT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY YEAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY YEAST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BATCH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADHERENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADHERENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FED-BATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FED-BATCH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PERFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PERFUSION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY OUTSOURCED/CDMO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY OUTSOURCED/CDMO, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GENE EDITING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RESEARCH & DEVELOPEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RESEARCH & DEVELOPEMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY HEPATIC DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY HEPATIC DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY METABOLIC/ENDOCRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY METABOLIC/ENDOCRINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 149. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 151. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 153. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RARE GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RARE GENETIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 155. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 157. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
  • TABLE 159. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 161. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 163. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2025-2030 (USD MILLION)
  • TABLE 165. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2030 (USD MILLION)
  • TABLE 167. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2030 (USD MILLION)
  • TABLE 169. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2025-2030 (USD MILLION)
  • TABLE 171. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2025-2030 (USD MILLION)
  • TABLE 173. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2025-2030 (USD MILLION)
  • TABLE 175. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
  • TABLE 177. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 179. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 181. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 183. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 185. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 187. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 188. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
  • TABLE 189. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 192. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 193. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2024 (USD MILLION)
  • TABLE 194. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2025-2030 (USD MILLION)
  • TABLE 195. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
  • TABLE 196. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2030 (USD MILLION)
  • TABLE 197. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
  • TABLE 198. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2030 (USD MILLION)
  • TABLE 199. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 200. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2025-2030 (USD MILLION)
  • TABLE 201. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2025-2030 (USD MILLION)
  • TABLE 203. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2025-2030 (USD MILLION)
  • TABLE 205. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 206. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
  • TABLE 207. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 208. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 209. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 211. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 212. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 213. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 215. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 217. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 218. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
  • TABLE 219. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 221. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 222. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 223. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2024 (USD MILLION)
  • TABLE 224. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2025-2030 (USD MILLION)
  • TABLE 225. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
  • TABLE 226. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2030 (USD MILLION)
  • TABLE 227. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
  • TABLE 228. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2030 (USD MILLION)
  • TABLE 229. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 230. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2025-2030 (USD MILLION)
  • TABLE 231. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2024 (USD MILLION)
  • TABLE 232. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2025-2030 (USD MILLION)
  • TABLE 233. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2024 (USD MILLION)
  • TABLE 234. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2025-2030 (USD MILLION)
  • TABLE 235. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 236. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
  • TABLE 237. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 238. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 239. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 241. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 242. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 243. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 245. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 246. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
  • TABLE 247. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 249. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 250. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 251. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2024 (USD MILLION)
  • TABLE 252. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2025-2030 (USD MILLION)
  • TABLE 253. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
  • TABLE 254. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2030 (USD MILLION)
  • TABLE 255. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
  • TABLE 256. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2030 (USD MILLION)
  • TABLE 257. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 258. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2025-2030 (USD MILLION)
  • TABLE 259. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2024 (USD MILLION)
  • TABLE 260. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2025-2030 (USD MILLION)
  • TABLE 261. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2024 (USD MILLION)
  • TABLE 262. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2025-2030 (USD MILLION)
  • TABLE 263. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 264. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
  • TABLE 265. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 267. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 269. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2024 (USD MILLION)
  • TABLE 270. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2025-2030 (USD MILLION)
  • TABLE 271. BRAZIL V